SEATTLE, July 22, 2021, (MEDGADGET) — Global Pneumococcal Vaccines Market Analysis
Overview
The pneumococcal vaccination is intended to protect against infection caused by the bacterium Streptococcus pneumonia. Pneumococcal vaccinations are divided into two types: pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine.
Pneumococcal conjugate vaccination is recommended for all children under the age of two, all adults 65 and older, and individuals aged 2-64 with specific medical problems, according to the CDC (Centers for Disease Control and Prevention). All adults 65 and older, people 2-64 years old with certain medical problems, and individuals 19-64 years old who smoke cigarettes should get the pneumococcal polysaccharide vaccination, according to the CDC.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/2295
The global pneumococcal vaccines market was projected to be worth US$ 7,376.6 million in 2018 and is set to grow at a CAGR of 7.5 percent between 2018 and 2026.
Drivers
The global pneumococcal vaccines market is forecast to develop as producers form more partnerships with various organizations.
Pneumococcal vaccine usage is projected to increase during the forecast period owing to increasing pneumonia incidence among the world population. As per the World Health Organization (WHO), pneumonia caused 16 percent of all fatalities in children under the age of five in 2015, accounting for 920,136 fatalities worldwide.
In addition, a growing relationship between the Global Alliance for Vaccinations and Immunization (GAVI) and key vendors to supply pneumococcal vaccines in emerging nations is likely to be a major driving factor for the market. GSK (Glaxo Smith Kline) stated in March 2016 that the pneumococcal vaccination would be available at the lowest price – US$ 3.05 starting in 2017, down 10% from the 2016 price (US$ 3.40). Using a tiered pricing system, developing nations may fulfill vaccination needs for vast segments of the target population. This pricing is planned to be offered to all GAVI nations under the experimental Advance Market Commitment (AMC). Furthermore, after the transfer, the vaccine will be marketed at the same price for the next ten years.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2295
Regional Insights
The global pneumococcal vaccines market is projected to be dominated by North America. This is due in large part to the presence of significant firms in the region who are engaged in obtaining regulatory approvals for innovative pneumococcal vaccines. Furthermore, the rising mortality rate linked with pneumonia, as well as increased awareness of pneumonia infection and its underlying symptoms among the US population, are estimated to drive considerable market growth in the region during the forecast period. As per the American Lung Association, pneumonia and influenza caused 56,832 fatalities in the U.S. in 2013, making them the eighth highest factor of mortality.
Increased government effort to incorporate pneumococcal vaccination in their separate healthcare vaccination programs, as well as expanding healthcare infrastructure in developing markets such as China and India, all result in greater pneumococcal vaccine use in Asia Pacific. Pfizer, Inc.’s pneumococcal vaccine Prevenar 13, which is designed to help prevent pneumococcal illness in babies aged 6 weeks to 15 months, was authorized by the China Food and Drug Administration (CFDA) in November 2016.
In addition, in 2017, the Indian government, in conjunction with GAVI, offered low-cost Pneumococcal Conjugate Vaccine (PCV) vaccinations in three states throughout the country. Furthermore, 60 percent of all GAVI-procured vaccines would be made in India under this cooperation.
During the forecast period, these actions, together with increased vaccine licensing, are impelling the growth of the Asia Pacific pneumococcal vaccines market.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/pneumococcal-vaccines-market-to-surpass-us-131943-million-by-2026-1192
Competitive Landscape
Certain producers are concentrating on new initiatives aimed at illnesses for which there is now no vaccination for various age groups. Merck, which is known outside of the U.S. as MSD, began two Phase 3 trials for PCV-15 (V114), an experimental polyvalent conjugate vaccine against pneumococcal illness, in April 2018.
Major companies contributing in the global pneumococcal vaccines market are Merck & Co. Inc., GlaxoSmithKline plc., and Pfizer, Inc.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Vaccine Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Pipeline Analysis
- Strategic Collaborations
- Government Fundings and Support
- Reimbursement Scenario
- GAVI and PATH Program Details
- Supply Shortage Scenario
- Epidemiology
- Target Age Group Analysis
- PEST Analysis
- Market Dynamics
- Global Pneumococcal Vaccines Market, By Vaccine Type, 2016 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- PCV10
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- PCV13
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- PPSV23
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Introduction
- Global Pneumococcal Vaccines Market, By Distribution Channel, 2016 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Introduction
- Global Pneumococcal Vaccines Market, By Region, 2016 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, By Region, 2016 – 2026
- Regional Trends
- North America
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- Northern Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Have a Look at Related Research Insights:
Plant-Based Biologics Market To Surpass US$ 24.9 Million By 2027
Coronavirus Vaccine Market To Surpass US$ 95,988.0 Million By 2028
Plasmid DNA Manufacturing Market To Surpass US$ 2,733.8 Million By 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837